flucytosine has been researched along with Cancer of Ovary in 14 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of human epithelial ovarian cancer cell line (SKOV-3, an ovarian adenocarcinoma derived from the ascites of an ovarian cancer patient) with the prodrugs 5-fluorocytosine (5-FC) or camptothecin-11 (CPT-11) in the presence of HB1." | 1.36 | Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. ( Choi, KC; Jeung, EB; Kim, KY; Kim, SU; Leung, PC, 2010) |
| "The Ovcar-5 and Skov-3 ovarian cancer cell lines exposed to the Ad-Lp-CD adenoviral vector were much more sensitive to the prodrug 5-fluorocytosine (5FC), which is converted from the 5FC prodrug into the toxic chemical 5-fluorouracil, than was the CCD minimal deviation fibroblast cell line after exposure to the same vector." | 1.31 | The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. ( Crystal, R; Deisseroth, A; Fujii, T; Kacinski, B; Leavitt, J; Peng, XY; Pizzorno, G; Rutherford, T; Sapi, E; Schwartz, P; Won, JH; Zelterman, D, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Isoda, L | 1 |
| Sonoda-Fukuda, E | 1 |
| Fujino, H | 1 |
| Takarada, T | 1 |
| Hasegawa, K | 1 |
| Kasahara, N | 1 |
| Kubo, S | 1 |
| Hartkopf, AD | 1 |
| Bossow, S | 1 |
| Lampe, J | 1 |
| Zimmermann, M | 1 |
| Taran, FA | 1 |
| Wallwiener, D | 1 |
| Fehm, T | 1 |
| Bitzer, M | 1 |
| Lauer, UM | 1 |
| Jiang, J | 1 |
| Wei, D | 1 |
| Sun, L | 1 |
| Wang, Y | 1 |
| Wu, X | 1 |
| Li, Y | 1 |
| Fang, Z | 1 |
| Shang, H | 1 |
| Wei, Z | 1 |
| Kim, KY | 1 |
| Kim, SU | 1 |
| Leung, PC | 1 |
| Jeung, EB | 1 |
| Choi, KC | 1 |
| Sher, YP | 1 |
| Chang, CM | 1 |
| Juo, CG | 1 |
| Chen, CT | 1 |
| Hsu, JL | 1 |
| Lin, CY | 1 |
| Han, Z | 1 |
| Shiah, SG | 1 |
| Hung, MC | 1 |
| Yao, Y | 1 |
| Peng, Z | 1 |
| Wang, H | 2 |
| Li, Q | 1 |
| Liu, S | 1 |
| Akbulut, H | 1 |
| Zhang, L | 1 |
| Tang, Y | 1 |
| Deisseroth, A | 2 |
| Chung, I | 1 |
| Deisseroth, AB | 1 |
| Kong, BH | 1 |
| Song, Y | 1 |
| Ma, DX | 1 |
| Qu, X | 1 |
| Jiang, S | 1 |
| Cai, LQ | 1 |
| Li, M | 1 |
| Lu, S | 1 |
| Wang, HB | 1 |
| Wang, ZH | 1 |
| Wang, Z | 1 |
| Cai, L | 1 |
| Chalikonda, S | 1 |
| Kivlen, MH | 1 |
| O'Malley, ME | 1 |
| Eric Dong, XD | 1 |
| McCart, JA | 1 |
| Gorry, MC | 1 |
| Yin, XY | 1 |
| Brown, CK | 1 |
| Zeh, HJ | 1 |
| Guo, ZS | 1 |
| Bartlett, DL | 1 |
| Xie, Y | 1 |
| Gilbert, JD | 1 |
| Kim, JH | 1 |
| Freytag, SO | 1 |
| Peng, XY | 1 |
| Won, JH | 1 |
| Rutherford, T | 1 |
| Fujii, T | 1 |
| Zelterman, D | 1 |
| Pizzorno, G | 1 |
| Sapi, E | 1 |
| Leavitt, J | 1 |
| Kacinski, B | 1 |
| Crystal, R | 1 |
| Schwartz, P | 1 |
14 other studies available for flucytosine and Cancer of Ovary
| Article | Year |
|---|---|
Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer.
Topics: Animals; Cell Line, Tumor; Cytosine Deaminase; Female; Flucytosine; Genetic Therapy; Genetic Vectors | 2023 |
Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase.
Topics: Cell Line, Tumor; Cytosine Deaminase; Female; Flucytosine; Genetic Therapy; Humans; Measles Vaccine; | 2013 |
A preliminary study on the construction of double suicide gene delivery vectors by mesenchymal stem cells and the in vitro inhibitory effects on SKOV3 cells.
Topics: Adenoviridae; Antimetabolites; Base Sequence; Cell Proliferation; Coculture Techniques; Cytosine Dea | 2014 |
Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth.
Topics: Animals; Antimetabolites; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cell Line, Tum | 2010 |
Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth.
Topics: Animals; Cell Line, Tumor; Cytosine Deaminase; Endostatins; Female; Flucytosine; Gene Fusion; Geneti | 2013 |
[Anticancer effects of cytosine deaminase gene/5-fluorocytosine therapies to ovarian cancer in vivo].
Topics: Adenoviridae; Animals; Antimetabolites; Cytosine Deaminase; Female; Flucytosine; Genetic Therapy; Hu | 2002 |
Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Breast Neoplasms; Cell Death; Colonic Neoplasms; Cyt | 2003 |
Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.
Topics: Adenoviridae; Artificial Gene Fusion; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytosi | 2004 |
[In vitro treatment of ovarian cancer cells with cytosine deaminase-thymidine kinase fusion disuicide gene therapy system under the control of human telomerase reverse transcriptase gene promoter].
Topics: Cystadenocarcinoma, Serous; Cytosine Deaminase; DNA-Binding Proteins; Female; Flucytosine; Ganciclov | 2004 |
[Killing effect of adenovirus mediated fusion gene cytosine and deaminase uracil phosphoribosyl transferase directed by glutathione S-transferase P1 promoter on cisplatin-resistant ovarian cancer cells in vitro].
Topics: Adenoviruses, Human; Antineoplastic Agents; Cisplatin; Cytosine Deaminase; Drug Resistance, Neoplasm | 2004 |
Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents; Artificial Gene Fusion; Cell Growth Processes; | 2005 |
Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.
Topics: Animals; Antimetabolites; Carcinoma; Cell Line, Tumor; Combined Modality Therapy; Cytosine Deaminase | 2008 |
Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy.
Topics: Adenoviridae; Animals; Antiviral Agents; Cytosine Deaminase; Female; Flucytosine; Ganciclovir; Genes | 1999 |
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Topics: Adenoviridae; Animals; Cytomegalovirus; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Gene | 2001 |